文献速递乳腺癌

预测亚洲乳腺癌患者携带BRCA1或BRCA2突变的可能性

Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer.
PubMed 文献 · J Clin Oncol · 2022-02-10

本研究基于8162例亚洲乳腺癌患者的胚系BRCA基因检测结果,构建了亚洲风险计算器模型,纳入诊断年龄、 ethnicity、双侧乳腺癌、肿瘤标志物及家族史等预测因子,模型区分度AUC为0.80(95%CI 0.75-0.84),校准良好(Hosmer-Lemeshow P=0.614)。在现有临床基因检测标准中加入肿瘤分级后,转诊进行遗传咨询和检测的患者比例从37%降至33%(P=0.003)。结论认为,人群特异性定制突变预测模型和临床基因检测标准可提高亚洲患者BRCA突变预测的准确性。

要点

  • 亚洲风险计算器纳入诊断年龄、 ethnicity、双侧乳腺癌、肿瘤标志物和家族史作为预测因子。
  • 模型区分度AUC为0.80(95%CI 0.75-0.84),校准Hosmer-Lemeshow P=0.614。
  • 在针对45岁以下乳腺癌患者的现有临床基因检测标准中加入肿瘤分级,转诊比例从37%降至33%(P=0.003)。

核心结论

  • 人群特异性定制突变预测模型和临床基因检测标准提高了亚洲患者BRCA突变预测的准确性。

研究设计与样本

  • 横断面基于人群的研究,纳入8162例亚洲乳腺癌患者,使用胚系BRCA基因检测结果构建新模型(亚洲风险计算器),并与现有突变预测模型比较性能。

主要发现

  • 亚洲风险计算器纳入诊断年龄、 ethnicity、双侧乳腺癌、肿瘤标志物和乳腺癌或卵巢癌家族史作为预测因子。
  • 纳入肿瘤分级显著改善了模型性能。
  • 完整模型校准良好(Hosmer-Lemeshow P值=0.614),区分BRCA与非BRCA致病变异携带者的AUC为0.80(95%CI 0.75-0.84)。
  • 在针对45岁以下乳腺癌患者的现有临床基因检测标准中加入分级后,转诊进行遗传咨询和检测的患者比例从37%降至33%(P值=0.003),从而提高了总体效率。

关键数值与推荐

  • 亚洲风险计算器预测因子包括诊断年龄、 ethnicity、双侧乳腺癌、肿瘤标志物和乳腺癌或卵巢癌家族史。
  • 模型区分度AUC为0.80(95%CI 0.75-0.84),校准Hosmer-Lemeshow P值=0.614。
  • 在现有临床基因检测标准(针对45岁以下乳腺癌患者)中加入肿瘤分级后,转诊比例从37%降至33%(P值=0.003)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: With the development of poly (ADP-ribose) polymerase inhibitors for treatment of patients with cancer with an altered BRCA1 or BRCA2 gene, there is an urgent need to ensure that there are appropriate strategies for identifying mutation carriers while balancing the increased demand for and cost of cancer genetics services. To date, the majority of mutation prediction tools have been developed in women of European descent where the age and cancer-subtype distributions are different from that in Asian women. METHODS: In this study, we built a new model (Asian Risk Calculator) for estimating the likelihood of carrying a pathogenic variant in BRCA1 or BRCA2 gene, using germline BRCA genetic testing results in a cross-sectional population-based study of 8,162 Asian patients with breast cancer. We compared the model performance to existing mutation prediction models. The models were evaluated for discrimination and calibration. RESULTS: Asian Risk Calculator included age of diagnosis, ethnicity, bilateral breast cancer, tumor biomarkers, and family history of breast cancer or ovarian cancer as predictors. The inclusion of tumor grade improved significantly the model performance. The full model was calibrated (Hosmer-Lemeshow P value = .614) and discriminated well between BRCA and non-BRCA pathogenic variant carriers (area under receiver operating curve, 0.80; 95% CI, 0.75 to 0.84). Addition of grade to the existing clinical genetic testing criteria targeting patients with breast cancer age younger than 45 years reduced the proportion of patients referred for genetic counseling and testing from 37% to 33% (P value = .003), thereby improving the overall efficacy. CONCLUSION: Population-specific customization of mutation prediction models and clinical genetic testing criteria improved the accuracy of BRCA mutation prediction in Asian patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ang BH, Ho WK, Wijaya E, et al. Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer. J Clin Oncol. 2022. PMID: 35143328. doi:10.1200/JCO.21.01647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。